REDUCTION IN THE POPULATION PREVALENCE OF HCV VIRAEMIA AMONG PEOPLE WHO INJECT DRUGS ASSOCIATED WITH SCALE-UP OF DIRECT-ACTING ANTIVIRAL THERAPY IN COMMUNITY DRUG SERVICES: REAL WORLD DATA.
暂无分享,去创建一个
P. Hayes | S. Hutchinson | M. Hickman | J. Dillon | R. Gunson | D. Goldberg | N. Palmateer | S. McDonald | A. McAuley | A. Yeung | S. Barclay | S. Shepherd | Shanley Smith
[1] L. Tavoschi,et al. HCV micro‐elimination in two prisons in Milan, Italy: A model of care , 2020, Journal of viral hepatitis.
[2] Z. Butt,et al. Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study , 2020, Open forum infectious diseases.
[3] H. Gage,et al. ITTREAT (Integrated Community Test ‐ Stage ‐ TREAT) Hepatitis C service for people who use drugs: Real‐world outcomes , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[4] M. Deutsch,et al. Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting , 2020, Annals of gastroenterology.
[5] P. Hayes,et al. Real‐world impact following initiation of interferon‐free hepatitis C regimens on liver‐related outcomes and all‐cause mortality among patients with compensated cirrhosis , 2019, Journal of viral hepatitis.
[6] P. Read,et al. Treatment adherence and support for people who inject drugs taking direct‐acting antiviral therapy for hepatitis C infection , 2019, Journal of viral hepatitis.
[7] Rachel Glass,et al. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol) , 2019, BMJ Open.
[8] G. Dore,et al. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. , 2019, Journal of hepatology.
[9] P. Vickerman,et al. High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme , 2018, Journal of viral hepatitis.
[10] J. Leung,et al. Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs , 2018, Addiction.
[11] J. Dillon,et al. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. , 2017, The International journal on drug policy.
[12] G. Dore,et al. Direct-acting antiviral agents for HCV infection affecting people who inject drugs , 2017, Nature Reviews Gastroenterology & Hepatology.
[13] J. Cairns,et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.
[14] M. Pedrosa,et al. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV) , 2015, Advances in Therapy.
[15] G. Dore,et al. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] C. Archibald,et al. Key findings from a national enhanced HIV surveillance system: 2010 - 2012. , 2014, Canada communicable disease report = Releve des maladies transmissibles au Canada.
[17] H. Innes,et al. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? , 2014, Gut.
[18] S. Hutchinson,et al. Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.
[19] J. Lazarus,et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.
[20] P. Hayes,et al. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan , 2014, Journal of viral hepatitis.
[21] J. Pawlotsky,et al. EASL recommendations on treatment of hepatitis C 2014. , 2014, Journal of hepatology.
[22] P. Vickerman,et al. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] P. Vickerman,et al. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. , 2012, Addiction.
[24] S. Hutchinson,et al. Detection of hepatitis C virus RNA in dried blood spots. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[25] Patrick Royston,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[26] J. Parry,et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots , 2003, Journal of medical virology.